22nd Annual Psychopharmacology Update

October 27, 2023 - October 28, 2023


Hyatt Regency Cincinnati Hotel
Cincinnati, Ohio





This activity is intended for pediatric, general, and geriatric psychiatrists, nurse practitioners, physician assistants, nurses, psychologists, social workers, and other mental health professionals engaged in the care of patients with psychiatric and mood disorders.  



[bold]Psychedelics & Psilocybin [/bold] [LIST] [ITEM]Describe current evidence for the clinical utility and safety of psychedelic assisted therapy in various psychiatric disorders. [ITEM]Review the psychedelic drug-therapy combinations in late-stage clinical trial development. [ITEM]Evaluate some of the key challenges to conducting psychedelic research and the impact on potential treatment programs from a regulatory perspective. [/LIST] [bold]Cannabis [/bold] [LIST] [ITEM]Outline the risks and potential utility of cannabis for the treatment of psychiatric conditions. [ITEM]Describe a risk stratification strategy to identify cannabis users who are most at risk for negative outcomes. [/LIST] [bold]Addiction[/bold] [LIST] [ITEM]Discuss the epidemiology of substance use disorders and their co-occurrence with other psychiatric disorders and review current recommended approaches for concurrent treatment. [ITEM]Review advances in the pharmacotherapy and psychotherapy of substance use disorders. [/LIST] [bold]Masterclass I: Brave New Psychopharmacology[/bold] [LIST] [ITEM]Assess the physiologic function of novel receptors in the brain and their role as potential therapeutic targets. [ITEM]Demonstrate greater confidence related to understanding the MOA of emerging treatments for mood and psychotic disorders.  [ITEM]Compare clinical data on the efficacy and safety of emerging psychotropic agents across psychiatric conditions.  [ITEM]Recognize where novel psychotropic agents may fit into the treatment paradigm for patients with mood and psychotic disorders.  [/LIST] [bold]Masterclass II: Judicious Psychopharmacology[/bold] [LIST] [ITEM]Assess the efficacy and safety of current pharmacotherapies (both on-label and off-label) for mood and psychotic disorders, including medication combinations and adjunctive therapies. [/LIST] [bold]Masterclass III: Creative Psychopharmacology[/bold] [LIST] [ITEM]Recognize the risk of treatment non-response and relapse in patients with mood and psychotic disorders. [ITEM]Discuss current definitions, criteria, and recent guidelines for treatment resistance in various psychiatric disorders. [ITEM]Evaluate therapeutic options for patients who have an inadequate response to treatment, including the use of combination and augmentation therapies. [/LIST] [bold]Masterclass IV: Strategic Psychopharmacology[/bold] [LIST] [ITEM]Develop individualized treatment plans for neuropsychiatric disorders using personalized medicine strategies. [ITEM]Incorporate novel approaches to the clinical management of complex psychiatric disorders. [/LIST] [bold]Masterclass V: Harm-Avoidance Psychopharmacology[/bold] [LIST] [ITEM]Review factors that impact the emergence of adverse effects of psychotropic drugs. [ITEM]Evaluate strategies to monitor for and manage adverse effects to improve patient adherence and optimize clinical outcomes. [/LIST]



[bold]Physician Accreditation [/bold] This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Global Academy for Medical Education. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians. [bold]Physician Credit Designation [/bold] The University of Cincinnati designates this Live Activity for a maximum of 15.5 [italic] AMA PRA Category 1 Credits™.[/italic] [bold]Maintenance of Certification [/bold] ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements. [JALOGOGAME][PIM] [bold]Jointly Accredited Provider [/bold] In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Academy for Medical Education. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. [bold]Continuing Nursing Education [/bold] The maximum number of hours awarded for this Continuing Nursing Education activity is 15.5 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be determined and indicated on your certificate. [bold]Continuing Pharmacy Education [/bold] Postgraduate Institute for Medicine designates this continuing education activity for 15.5 contact hours (1.350 CEUs) of the Accreditation Council for Pharmacy Education. [bold]Physician Assistants Credit Designation [/bold] The American Academy of Physician Assistants (AAPA) accepts [italic] AMA PRA Category 1 Credit(s)™[/italic] from organizations accredited by the ACCME. [bold]Disclosures & Conflict of Interest Resolution[/bold] UC and PIM adhere to ACCME Essential Areas, Standards, and Policies regarding industry support of continuing medical education, independence, and integrity. Disclosure of the planning committee and faculty's commercial relationships will be made known at the activity. Speakers are required to openly disclose any limitations of data and/or any discussion of any off-label, experimental, or investigational uses of drugs or devices in their presentations.

[bold][underline]Disclosure of Conflicts of Interest [/underline][/bold] Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity.